Subtype
Malignant Reproductive System Neoplasm
CI-CAN-00001172Explore in graph →
2,803 active trials38 approved drugs186 evidence items
- NCIt
- C36076
Loading cancer entity…
Loading cancer entity…
Subtype
CI-CAN-00001172Explore in graph →
Clinical trials
12,155 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
Computedformula ci-trial-intel-v1 · interventional studies · entity + NCIt descendants · hover a figure for its formulaCompare cancersTerminated studies (1,473)
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT03199586 | Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Treatment-Refractory Solid Tumor Malignancies | completed | Phase 1 | 23 | Novita Pharmaceuticals, Inc.INDUSTRY | 1 | Jul 20, 2025 | clinicaltrials |
| NCT04242199 | Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of INCB099280 in Participants With Advanced Solid Tumors | completed | Phase 1 | 182 | Incyte CorporationINDUSTRY | 5 | Jul 14, 2025 | clinicaltrials |
| NCT04580485 | INCB106385 Alone or in Combination With Immunotherapy in Advanced Solid Tumors | completed | Phase 1 | 54 | Incyte CorporationINDUSTRY | 6 | Jul 11, 2025 | clinicaltrials |
| NCT02611024 | Pharmacokinetic Study of Lurbinectedin in Combination With Irinotecan in Patients With Selected Solid Tumors | completed | Phase 1 / Phase 2 | 316 | PharmaMarINDUSTRY | 6 | Jul 9, 2025 | clinicaltrials |
| NCT01226316 | Safety, Tolerability & Potential Anti-cancer Activity of Increasing Doses of AZD5363 in Different Treatment Schedules | completed | Phase 1 | 285 | AstraZenecaINDUSTRY | 10 | Jun 29, 2025 | clinicaltrials |
| NCT02159716 | CART-meso in Mesothelin Expressing Cancers | completed | Phase 1 | 19 | University of PennsylvaniaOTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT04608409 | Dose Escalation of Lapatinib With Paclitaxel in Ovarian Cancer | completed | Phase 1 | 16 | Frederick R. Ueland, M.D.OTHER | 1 | Jun 29, 2025 | clinicaltrials |
| NCT05788484 | A Study of CDX-585 in Patients With Advanced Malignancies | completed | Phase 1 | 20 | Celldex TherapeuticsINDUSTRY | 1 | Jun 15, 2025 | clinicaltrials |
| NCT01351103 | A Study of LGK974 in Patients With Malignancies Dependent on Wnt Ligands | completed | Phase 1 | 185 | Novartis PharmaceuticalsINDUSTRY | 7 | Jun 13, 2025 | clinicaltrials |
| NCT05253053 | To Evaluate Efficacy and Safety of TT-00420 (Tinengotinib) as Monotherapy and Combination Therapy in Patients With Advanced Solid Tumors | completed | Phase 1 / Phase 2 | 84 | TransThera Sciences (Nanjing), Inc.INDUSTRY | 1 | Jun 12, 2025 | clinicaltrials |
| NCT06087289 | A Study to Evaluate the Safety of KAND567, in Combination With Carboplatin Therapy, in Women With Recurrent Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer(KANDOVA) | completed | Phase 1 / Phase 2 | 18 | Novakand Pharma ABINDUSTRY | 3 | Jun 8, 2025 | clinicaltrials |
| NCT05567601 | Doxil/Caelyx BE Study | completed | Phase 1 | 36 | Baxter Healthcare CorporationINDUSTRY | 1 | Jun 5, 2025 | clinicaltrials |
| NCT04068896 | Study of NGM120 in Subjects With Advanced Solid Tumors, Pancreatic Cancer, and Prostate Cancer Using Combination Therapy | completed | Phase 1 / Phase 2 | 89 | NGM Biopharmaceuticals, IncINDUSTRY | 1 | May 29, 2025 | clinicaltrials |
| NCT04811196 | A Study of Different Dosing Schedules of Selinexor in Sarcoma Patients | completed | Phase 1 | 56 | University Health Network, TorontoOTHER | 1 | May 29, 2025 | clinicaltrials |
| NCT02713386 | Ruxolitinib Phosphate, Paclitaxel, and Carboplatin in Treating Patients With Stage III-IV Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 147 | NRG OncologyOTHER | 1 | May 25, 2025 | clinicaltrials |
| NCT02672098 | Hyperthermic Intraperitoneal Chemotherapy for Recurrent Ovarian Cancer | completed | Phase 1 | 3 | Loma Linda UniversityOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT03508570 | Nivolumab With or Without Ipilimumab in Treating Patients With Recurrent or High Grade Gynecologic Cancer With Metastatic Peritoneal Carcinomatosis | completed | Phase 1 | 26 | M.D. Anderson Cancer CenterOTHER | 1 | May 22, 2025 | clinicaltrials |
| NCT06389695 | Pharmacokinetics, Biodistribution, Radiation Dose and Safety Study of 68Ga-NYM032 in Patients | completed | Phase 1 / Phase 2 | 20 | Norroy Bioscience Co., LTDINDUSTRY | 1 | May 21, 2025 | clinicaltrials |
| NCT00328614 | Samarium-153 With Neoadjuvant Hormonal and Radiation Therapy for Locally Advanced Prostate Cancer | completed | Phase 1 | 32 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 16, 2025 | clinicaltrials |
| NCT01420250 | Cabazitaxel With Radiation and Hormone Therapy for Prostate Cancer | completed | Phase 1 | 20 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT03784378 | Continued Access to RXDX-105 | completed | Phase 1 | 3 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | May 15, 2025 | clinicaltrials |
| NCT01848067 | Alisertib, Abiraterone Acetate and Prednisone in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 / Phase 2 | 9 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 4, 2025 | clinicaltrials |
| NCT02603965 | Copper Cu 64 TP3805 PET in Detecting Cancer in Patients With Prostate Cancer Undergoing Surgery | completed | Phase 1 | 25 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | May 2, 2025 | clinicaltrials |
| NCT02632448 | A Study of LY2880070 in Participants With Advanced or Metastatic Cancer | completed | Phase 1 / Phase 2 | 229 | Esperas Pharma Inc.OTHER | 4 | May 2, 2025 | clinicaltrials |
| NCT02339168 | Enzalutamide and Metformin Hydrochloride in Treating Patients With Hormone-Resistant Prostate Cancer | completed | Phase 1 | 25 | University of California, DavisOTHER | 1 | May 1, 2025 | clinicaltrials |
| NCT03054298 | CAR T Cells in Mesothelin Expressing Cancers | completed | Phase 1 | 65 | University of PennsylvaniaOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT03076203 | Phase IB Trial of Radium-223 and Niraparib in Patients With Castrate Resistant Prostate Cancer (NiraRad) | completed | Phase 1 | 14 | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson UniversityOTHER | 1 | Apr 29, 2025 | clinicaltrials |
| NCT00516724 | Study to Assess the Safety and Tolerability of a PARP Inhibitor in Combination With Carboplatin and/or Paclitaxel | completed | Phase 1 | 189 | AstraZenecaINDUSTRY | 3 | Apr 11, 2025 | clinicaltrials |
| NCT00436254 | Vaccine Therapy With Sargramostim (GM-CSF) in Treating Patients With Her-2 Positive Stage III-IV Breast Cancer or Ovarian Cancer | completed | Phase 1 | 66 | University of WashingtonOTHER | 1 | Apr 6, 2025 | clinicaltrials |
| NCT04925284 | Study of XB002 in Subjects With Solid Tumors (JEWEL-101) | completed | Phase 1 | 269 | ExelixisINDUSTRY | 9 | Apr 4, 2025 | clinicaltrials |
| NCT03894618 | SL-279252 (PD1-Fc-OX40L) in Subjects With Advanced Solid Tumors or Lymphomas | completed | Phase 1 | 49 | Shattuck Labs, Inc.INDUSTRY | 4 | Apr 2, 2025 | clinicaltrials |
| NCT06377683 | Clinical Evaluation of 177Lu-DansyI-PSMA (LNC1011) in Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 8 | The First Affiliated Hospital of Xiamen UniversityOTHER | 1 | Apr 1, 2025 | clinicaltrials |
| NCT02922764 | A Study of RGX-104 in Patients With Advanced Lung & Endometrial Cancer | completed | Phase 1 | 146 | Inspirna, Inc.INDUSTRY | 1 | Mar 26, 2025 | clinicaltrials |
| NCT00638898 | Busulfan, Melphalan, Topotecan Hydrochloride, and a Stem Cell Transplant in Treating Patients With Newly Diagnosed or Relapsed Solid Tumor | completed | Phase 1 | 25 | City of Hope Medical CenterOTHER | 1 | Mar 20, 2025 | clinicaltrials |
| NCT02649790 | Study of the Safety, Tolerability and Efficacy of KPT-8602 in Participants With Relapsed/Refractory Cancer Indications | completed | Phase 1 / Phase 2 | 277 | Karyopharm Therapeutics IncINDUSTRY | 5 | Mar 19, 2025 | clinicaltrials |
| NCT06559007 | Phase 1 Study to Evaluate PK, Safety, and Tolerability of HRS-5041 in Healthy Caucasian Male Participants | completed | Phase 1 | 24 | Atridia Pty Ltd.INDUSTRY | 1 | Mar 18, 2025 | clinicaltrials |
| NCT03206047 | Atezolizumab, Guadecitabine, and CDX-1401 Vaccine in Treating Patients With Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Cancer | completed | Phase 1 / Phase 2 | 12 | National Cancer Institute (NCI)NIH | 1 | Mar 13, 2025 | clinicaltrials |
| NCT05332340 | Safety, Tolerability and Pharmacokinetics (PK) Evaluation of BZ371A, Topically Administered | completed | Phase 1 | 12 | Biozeus Biopharmaceutical S.A.INDUSTRY | 1 | Mar 7, 2025 | clinicaltrials |
| NCT04428203 | Epidiolex (CBD) in Patients With Biochemically Recurrent Prostate Cancer | completed | Phase 1 | 21 | Zin W MyintOTHER | 1 | Mar 5, 2025 | clinicaltrials |
| NCT01792687 | Safety, Tolerability, Pharmacokinetics, and Preliminary Anti-tumor Activity of Ascending Doses of ARN 509 in Combination With Abiraterone Acetate | completed | Phase 1 | 6 | Aragon Pharmaceuticals, Inc.INDUSTRY | 1 | Mar 4, 2025 | clinicaltrials |
| NCT03073395 | Preliminary Evaluation of Uptake of [68Ga]P16-093 in Metastatic Prostate and Renal Cancer | completed | Phase 1 | 30 | Five Eleven Pharma, Inc.INDUSTRY | 1 | Feb 26, 2025 | clinicaltrials |
| NCT03805594 | 177Lu-PSMA-617 and Pembrolizumab in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | completed | Phase 1 | 43 | University of California, San FranciscoOTHER | 1 | Feb 25, 2025 | clinicaltrials |
| NCT01220154 | Study of Intraperitoneal Carboplatin With IV Paclitaxel and Bevacizumab in Untreated Ovarian Cancer | completed | Phase 1 | 9 | David O'MalleyOTHER | 1 | Feb 21, 2025 | clinicaltrials |
| NCT03552471 | Mirvetuximab Soravtansine and Rucaparib Camsylate in Treating Participants With Recurrent Endometrial, Ovarian, Fallopian Tube or Primary Peritoneal Cancer | completed | Phase 1 | 25 | Ohio State University Comprehensive Cancer CenterOTHER | 1 | Feb 13, 2025 | clinicaltrials |
| NCT04805333 | Phase 1 Dose Escalation of ArtemiCoffee | completed | Phase 1 | 13 | Frederick R. Ueland, M.D.OTHER | 1 | Feb 10, 2025 | clinicaltrials |
| NCT01638533 | Romidepsin in Treating Patients With Lymphoma, Chronic Lymphocytic Leukemia, or Solid Tumors With Liver Dysfunction | completed | Phase 1 | 37 | National Cancer Institute (NCI)NIH | 2 | Feb 7, 2025 | clinicaltrials |
| NCT04406623 | Phase 1 Study of SL-172154 (SIRPα-Fc-CD40L) in Subjects With Ovarian Cancer | completed | Phase 1 | 27 | Shattuck Labs, Inc.INDUSTRY | 1 | Jan 30, 2025 | clinicaltrials |
| NCT04703920 | Talazoparib in Combination With Belinostat for Metastatic Breast Cancer, Metastatic Castration Resistant Prostate Cancer, and Metastatic Ovarian Cancer | completed | Phase 1 | 26 | University of Michigan Rogel Cancer CenterOTHER | 1 | Jan 23, 2025 | clinicaltrials |
| NCT03667716 | COM701 (an Inhibitor of PVRIG) in Subjects With Advanced Solid Tumors. | completed | Phase 1 | 121 | Compugen LtdINDUSTRY | 1 | Jan 17, 2025 | clinicaltrials |
| NCT04487847 | 18F-PSMA-1007 PET Imaging to Detect Primary Prostate Cancer(PICture) | completed | Phase 1 / Phase 2 | 75 | Radboud University Medical CenterOTHER | 1 | Jan 16, 2025 | clinicaltrials |
Data updated 22 days agoSource updated Jul 20, 2025source: clinicaltrials